Exchange: NASDAQ·Updated 05:13 PM EDT
Upcoming Earnings: Q2 '26

Reports: Aug 05After Hours

Estimated EPS

-$0.25

Estimated Rev

$14.41M

• Reported GAAP EPS of -$0.13 up 66.67% YoY • Reported revenue of $14.31M up 39.53% YoY

Bullish Takeaway

Coherus Oncology achieved strong LOQTORZI revenue growth and patient demand during the second quarter while successfully advancing multiple next-generation oncology pipeline programs toward anticipated clinical data readouts in 2H 2026.

Bearish Takeaway

Coherus Oncology continues to report net losses from continuing operations, a significant decline in cash and marketable securities, and ongoing risks associated with clinical development and future capital funding requirements.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q2 '26
-$0.25
--
--
N/A
Q1 '26
-$0.26
-$0.27
-2.53%
MISSED
Q4 '25
-$0.36
-$0.39
-9.83%
MISSED
Q3 '25
-$0.35
-$0.31
12.41%
BEAT
Q2 '25
-$0.22
-$0.39
-77.00%
MISSED

Advertisement|Remove ads.